Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin Liwei MengLiming HuangWei Zhang Review Article 03 August 2019 Pages: 3 - 7
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development Gesuino AngiusSilverio TomaoFederica Tomao Review Article 11 September 2019 Pages: 9 - 20
Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia Susanna E. Medellin-GaribayNadia Hernández-VillaSilvia Romano-Moreno Original Article 31 October 2019 Pages: 21 - 31
The secondary metabolites produced by Lactobacillus plantarum downregulate BCL-2 and BUFFY genes on breast cancer cell line and model organism Drosophila melanogaster: molecular docking approach Melih SentürkFahriye ErcanSerap Yalcin Original Article 31 October 2019 Pages: 33 - 45
Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid) Bahareh KashaniZahra ZandiSeyed H. Ghaffari Original Article 30 November 2019 Pages: 47 - 59
Cognitive impairments in breast cancer survivors treated with chemotherapy: a study based on event-related potentials Zhou XuFeng LuoLing-quan Kong Original Article 19 November 2019 Pages: 61 - 67
Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma Juanfang LiuShanshan XieXinwei Han Original Article 07 December 2019 Pages: 69 - 76
Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer Yang ZhaoLijuan WeiFangxuan Li Original Article 16 December 2019 Pages: 77 - 93
Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia Hui LiQiong XuJianxin Li Original Article 01 November 2019 Pages: 95 - 103
Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy Luigi RossiMonica VerricoFederica Tomao Original Article 21 November 2019 Pages: 105 - 111
Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach Chenfei ZhouTao MaJun Zhang Original Article 05 November 2019 Pages: 113 - 119
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors Anne SchettSacha I. RothschildMarkus Joerger Original Article 19 November 2019 Pages: 121 - 131
Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma Melissa J. GarwoodEliza A. HawkesGeoffrey Chong Original Article 17 December 2019 Pages: 133 - 140
Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development Pawat PattarawatShelby WallaceHwa-Chain Robert Wang Original Article 21 December 2019 Pages: 141 - 152
Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan Mansour PoorebrahimSolmaz SadeghiLadan Teimoori-Toolabi Original Article 28 November 2019 Pages: 153 - 171
Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors Su Young JungJi Seob YugJangik I. Lee Original Article 30 October 2019 Pages: 173 - 183
Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design Sen ZouJuanjuan LiuZhaoyong Yang Original Article 19 November 2019 Pages: 185 - 193
Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation Haidi HuangXin WangWanglin Jiang Original Article 07 December 2019 Pages: 195 - 204
Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer Liang HuangXiaojia WangZhimin Shao Original Article Open access 14 December 2019 Pages: 205 - 215
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B Satoshi YukiKatsunori ShinozakiMasaki Mori Clinical Trial Report 25 November 2019 Pages: 217 - 223
PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity Shaun D. FontaineAngelo D. SantiDaniel V. Santi Short Communication 09 November 2019 Pages: 225 - 229
A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions Nikki de RouwSabine VisserRob ter Heine Short Communication Open access 18 December 2019 Pages: 231 - 235
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation Ou YamaguchiKyoichi KairaHiroshi Kagamu Correction 08 November 2019 Pages: 237 - 239